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Objectives The aim of this study was to analyze the long-term follow-up of dilated cardiolaminopathies.
Background Lamin A/C (LMNA) gene mutations cause a variety of phenotypes. In the cardiology setting, patients diagnosed
with idiopathic dilated cardiomyopathy (DCM) plus atrioventricular block (AVB) constitute the majority of re-
ported cases.
Methods Longitudinal retrospective observational studies were conducted with 27 consecutive families in which LMNA
gene defects were identified in the probands, all sharing the DCM phenotype.
Results Of the 164 family members, 94 had LMNA gene mutations. Sixty of 94 (64%) were phenotypically affected
whereas 34 were only genotypically affected, including 5 with pre-clinical signs. Of the 60 patients, 40 had DCM
with AVB, 12 had DCM with ventricular tachycardia/fibrillation, 6 had DCM with AVB and Emery-Dreifuss muscu-
lar dystrophy type 2 (EDMD2), and 2 had AVB plus EDMD2. During a median of 57 months (interquartile range
36 to 107 months), we observed 49 events in 43 DCM patients (6 had a later event, excluded from the analy-
sis). The events were related to heart failure (15 heart transplants, 1 death from end-stage heart failure) and
ventricular arrhythmias (15 sudden cardiac deaths and 12 appropriate implantable cardioverter-defibrillator in-
terventions). By multivariable analysis, New York Heart Association functional class III to IV and highly dynamic
competitive sports for 10 years were independent predictors of total events. By a bivariable Cox model, splice
site mutations and competitive sport predicted sudden cardiac death.
Conclusions Dilated cardiomyopathies caused by LMNA gene defects are highly penetrant, adult onset, malignant diseases
characterized by a high rate of heart failure and life-threatening arrhythmias, predicted by New York Heart Asso-
ciation functional class, competitive sport activity, and type of mutation. (J Am Coll Cardiol 2008;52:1250–60)
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inked to a variety of clinical phenotypes (1–3), the majority
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ccepted June 23, 2008.ith cardiac involvement (1–5). Patients with LMNA gene
utations usually come to the attention of cardiologists
ecause of dilated cardiomyopathy (DCM) plus atrioven-
ricular block (AVB [MIM#115200]) (4–6), DCM plus
See page 1261
VB and Emery-Dreifuss muscular dystrophy type 2
EDMD2 [MIM#181350]) (7–9), different types of myop-
thies (10,11), or overlapping syndromes including DCM,
VB, and/or arrhythmias (2,12–14). In the cardiology
etting, patients diagnosed with DCM plus AVB constitute
he majority of reported “cardiolaminopathies,” with AVB
eing a useful clinical marker to orient the search for LMNA
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October 7, 2008:1250–60 Event Predictors in Dilated Cardiolaminopathiesene mutations in patients with DCM (4,5,15). Sudden
ardiac death (SCD) is a major clinical problem among all
ersons with LMNA mutations, 46% of whom have been
eported to die suddenly (16,17). Information on incremen-
al risk factors and prognostic stratification is limited both
or persons with the mutations in general and for cardio-
aminopathy patients in particular (11).
We investigated associations between genetic/nongenetic
actors and long-term outcome in a cohort of DCM-
ffected families with LMNA mutations.
ethods
etting and study design. This retrospective longitudinal
tudy was conducted with a series of 27 consecutive families
hose proband was diagnosed with a dilated cardiolamin-
pathy at our institution up to August 2006. The DCM was
iagnosed based on World Health Organization criteria
18). Until 1994, we screened DCM patients and their
amily members when the pedigree suggested a familial
isease. Since 1995, we have conducted serial family screen-
ng for all DCM patients (19). Criteria for search for the
MNA gene in DCM patients evolved during the study
eriod according to current concepts (4–10,15–17,20,21).
n brief, identification of the probands was based on the
o-existence of isolated DCM with AVB (n  21); DCM
ith AVB and EDMD2 (n 4); and DCM and ventricular
achycardia/fibrillation (n  2). We explored the associa-
ions between LMNA gene defects and phenotypic charac-
eristics at presentation in our center and a history of highly
ynamic competitive sports classified according to current
uidelines (22). The patients were either phenotypically
ealthy or not aware of their status at the time of their
thletic competitive activity. The mean interval that elapsed
etween the diagnosis and cessation of the competitive sport
ctivities was 14.7 10.2 years (median 12 years; range 0 to
6 years). Only 2 patients were agonistically active at the
ime of the diagnosis. We also assessed associations with
utcome, and attempted prognostic stratification. The local
thics committee approved the study.
amily screening protocol. After giving informed consent,
ll probands and relatives received genetic counseling and
linical screening and underwent peripheral blood sampling
or genetic testing. On confirming full comprehension of
he screening protocol, each mutated person (or legal
uardians of minors) received the written and signed report
escribing the identified mutation. Regular clinical moni-
oring was planned every 24 months for children and
dolescents without instrumental abnormalities, and every
2 months for adults with electrocardiographic or echocar-
iographic abnormalities who did not fulfill criteria for the
iagnosis of DCM or had DCM in functional class I and
ppropriate treatment, and at shorter intervals based on
linical needs. Clinical investigation included resting cardi-
logic evaluation, 12-lead electrocardiogram, 2-dimensional
nd echocardiography study (Doppler since 1978), 24-h iolter monitoring, effort test,
nd serum creatine phosphoki-
ase determination. The left
entricular end-diastolic diame-
er was calculated according to
he formula of Henry et al. (23).
euromuscular assessment of
robands and relatives was based
n detailed clinical history, phys-
cal examination, serum creatine
hosphokinase and serum lactate
etermination, and neuromyo-
ogic examination. When possi-
le, we traced the clinical and
athology records and autopsy
amples of deceased affected
elatives.
olecular analysis. The 12 ex-
ns of the LMNA gene were
mplified from peripheral blood-
erived genomic deoxyribonucleic acid by means of poly-
erase chain reaction, using primers derived from intronic
equences (5). The polymerase chain reaction fragments
ere analyzed by means of denaturing high-performance
iquid chromatography using the Wave deoxyribonucleic
cid fragment analysis system (Transgenomic, San Jose,
alifornia). Heteroduplex fragments were purified (QIA-
uick Kit, Qiagen, Santa Clarita, California) and then
equenced using a BigDye-terminator cycle sequencing
ystem (ABI PRISM, Applied Biosystems, Foster City,
alifornia). The LMNA gene analysis was performed by
irect bidirectional automated sequencing in case of pro-
ands with healthy parents, to exclude the rare possibility of
ecessive forms. The control series for each mutation is
onstituted of 196 normal persons. Reference sequences
sed in the study are as follows: LMNA gene: NCBI
C_000001; LMNA messenger ribonucleic acid: NCBI
M_170707; lamin A protein: NCBI NP_733821; LMNC
essenger ribonucleic acid: NCBI NM 005572; lamin C
rotein: NCBI NP005563.
tatistical analysis. The 94 subjects with mutations were
ncluded in the statistical analysis. Mutations were catego-
ized in two ways, based on type and position. Mutation
ypes were classified as: missense; intervening sequence (or
plice site) mutations predicting a skipped exon; or inser-
ions/deletions and stop mutations (ins-del/stop). The mu-
ations were also categorized by the two position clusters
eported by Hegele (24) to be associated with different
henotypic classes: mutations upstream of the nuclear lo-
alization signal spanning residues 416 to 423 (where no
utations have been found to date) versus downstream
utations (Fig. 1). Descriptive statistics were computed as
ean and standard deviation for continuous variables and as
ounts (percentages) for categorical variables. Median (in-
erquartile range) follow-up duration was calculated accord-
Abbreviations
and Acronyms
AVB  atrioventricular
block
DCM  dilated
cardiomyopathy
EDMD2  Emery-Dreifuss
muscular dystrophy type 2
HF  heart failure
ICD  implantable
cardioverter-defibrillator
ins-del/stop  insertions/
deletions and stop
mutations
LMNA  lamin A/C
LV  left ventricular
SCD  sudden cardiac
deathng to the inverse Kaplan-Meier method. The Student t
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Event Predictors in Dilated Cardiolaminopathies October 7, 2008:1250–60est, Fisher exact test, and test for trend were used to
ompare affected patients and phenotypically healthy muta-
ion carriers at baseline. Binomial exact confidence intervals
CIs) were computed for the age-related penetrance.
Follow-up started at first clinical assessment at our
enters and ended at the first occurrence of an event.
vent-free survival analysis was performed within the over-
ll study population of mutation carriers. Events were death
rom any cause, death from heart failure (HF), heart
ransplantation, and SCD, including appropriate implant-
ble cardioverter-defibrillator (ICD) interventions. Rates
er 100 person-years and their 95% binomial exact (95%)
Is were computed, as well as Kaplan-Meier cumulative
urvival (95% CI).
The log-rank test was used for univariable comparisons.
ox regression analysis was used to identify independent
redictors of events and to attempt prognostic stratification.
azard ratios and 95% CI were calculated. Variables reach-
ng p  0.2 at univariable analysis were included in the
ultivariable model, alongside mutation categories. Col-
inearity was observed between left ventricular (LV) ejection
raction and LV end-diastolic volume, and between age and
V ejection fraction and AVB. Therefore, LV ejection
raction was chosen based on clinical consensus as being the
ost common marker of LV function, and AVB was chosen
s the most prevalent and specific marker of the disease. The
Figure 1 Position of LMNA Gene Mutations
The position of lamin A/C (LMNA) gene mutations are shown according to the nuc
the NLS encodes the central alpha-helical rod domain, and the region downstream
and a deoxyribonucleic acid binding region. In red, we show missense, insertions/
sional reconstruction of the LMNA/C protein was made using Cn3D software, vers
the illustration emphasizes the rod domain (green worms) and the globular domainuber-White sandwich robust estimator of standard errors was used to account for intrafamilial aggregation of subjects.
he proportional hazards assumption was verified by means
f Schoenfeld residuals. The Harrell C statistic and the
hrinkage coefficient were computed to assess model dis-
rimination and calibration. Two-sided p values0.05 were
onsidered statistically significant. Stata 9.2 (StataCorp,
ollege Station, Texas) was used for all computation.
esults
tudy population and baseline characteristics. The dis-
ase was proved to be familial autosomal dominant in 21 of
he 27 families, likely familial autosomal dominant (based
n pedigree and family history) in 5, and associated with a
e novo mutation in 1. In 8 families, including that of the
e novo case, the proband was the only living mutated
ember. In the other 19 families, the number of living
utated members ranged from 2 to 12. Of the 137 relatives,
7 (49%) carried the corresponding proband mutation.
hus, a total of 94 LMNA mutated subjects (i.e., 27
robands, 67 relatives) entered the main analysis. The 23
MNA gene mutations identified in the 27 probands (6
ovel and 17 known) are listed in Table 1.
Of the 60 mutated and affected patients, 58 had a
henotype including DCM and 2 (son and daughter of a
atient with DCM, AVB, and EDMD2) had only AVB
calization signal (NLS) that spans residues 416 to 423: the region upstream of
NLS encodes the homology box, including the beta-immunoglobulin–like fold
ns, and stop mutations; in blue, intervening sequence mutations. The 3-dimen-
, by loading the 2 sequence proteins NP733821 and NP005563; in particular,
n and light blue worms) with respect to the NLS sequence.lear lo
of the
deletio
ion 4.1
(browith EDMD2. Of the 34 mutated nonaffected subjects, 5
Mutation Type, Position (Exons and Class With Respect to the NLS Region), Clinical Phenotypes, and Rate of Events per Family
Table 1 Mutation Type, Position (Exons and Class With Respect to the NLS Region), Clinical Phenotypes, and Rate of Events per Family
LMNA Gene Mutation Exon NLS Class Proband Phenotype
Familial/
De Novo
No. of
Families
No. of
Subjects Affected
Penetrance
Before 40 Yrs,
n (%)
No. of
Events
Rate of Events per
100 Person-Yrs
(95% CI)
SCD/ICD
Interventions
Rate of SCD per
100 Person-Yrs
(95% CI)
Missense Mutations
p.[Arg28Trp] 1 1 DCMAVB F proven 1 1 1 (100%) 1 (100%) 1 36.8 (5.2–260) 0 —
p.[Arg89Leu] 1 1 DCMAVB F proven 1 6 4 (67%) 3 (50%) 2 5.15 (1.2–20.6) 0 —
p.[Lys97Glu] 1 1 DCMAVB F proven 1 4 2 (50%) 2 (40%) 2 22.7 (5.7–91.1) 0 —
p.[Glu161Lys] 2 1 DCMAVB in
the 3 probands
F proven in 1,
not proven in
2 families
3 12 7 (60%) 1 (14%) 6 19.0 (8.5–42.3) 4 12.7 (4.7–33.8)
p.[Leu183Pro] 3 1 DCMAVB De novo 1 1 1 (100%) 1 (100) 0 — 0 —
p.[Arg190Trp] 3 1 DCMAVB F proven 1 6 3 (50%) 1 (33%) 2 5.9 (1.5–23.9) 1 2.9 (0.42–21.3)
p.[Lys219Thr] 4 1 DCMAVB F proven 1 4 3 (75%) 1 (33%) 0 — 0 —
p.[Lys260Asn] 4 1 DCMAVB F proven 1 1 1 (100%) 0 1 10.8 (1.5–76.6) 1 10.8 (1.5–76.6)
p.[Tyr267Cys] 1 DCMAVBEDMD2 F not proven 1 1 1 (100%) 1 (100%) 0 — 0 —
p.[Glu317Lys] 6 1 DCMAVB in both
families
F proven in
both families
2 6 3 (50%) 1 (16%) 2 3.7 (0.92–14.8) 1 1.8 (0.26–13.1)
p.[Arg377Leu] 6 1 DCMAVB F not proven 1 1 1 (100%) 0 1 72.2 (10.2–510) 1 72.2 (10.2–510)
p.[Trp498Arg] 9 2 DCMAVBEDMD2 F proven in
both families
1 2 2 (100%) 1 (50%) 2 9.1 (2.3–36.4) 2 9.1 (2.3–36.4)
p.[Ser573Leu] 9 2 DCMAVB in both
probands
F proven in
both families
2 12 3 (25%) 2 (16%) 3 6.2 (2.1–19.3) 1 2.1 (0.3–14.7)
p.[Arg644Cys] 1 2 DCMAVB F proven 1 2 1 (50%) 1 (100%) 1 16.4 (3.2–88.3) 0 —
Insertion/Deletions and Stop Mutations
c.del AGGTGG 212_8
p.[Glu68-Val69 Del]
1 1 DCMAVBEDMD2 F proven 1 5 4 (80%) 4 (80%) 1 6.6 (0.93-–7.3) 1 6.6 (0.93–47.3)
c.del C31,p.[Thr10fs85X] 1 1 DCMAVB F proven 1 6 5 (83%) 1 (16%) 5 38.4 (16.01–92.4) 5 38.4 (16.01–92.4)
p.[Glu111X] 1 1 DCMAVB F proven 1 4 2 (50%) 0 2 4.9 (1.12–17.9) 0 —
p.[Gln246X] 3 1 DCMAVB F proven 1 1 1 (100%) 0 0 — 0 —
c.ins C1525_6
p.[Pro509fs39X]
9 2 DCMAVBEDMD2 F proven 1 2 1 (50%) 1 (50%) 1 17.3 (2.4–120) 1 17.3 (2.4–120)
c.ins CTGC 1579_80
p.[Ile527fsX23]
9 2 DCMAVB F proven 1 3 3 (100%) 3 (100%) 2 6.7 (1.6–27.05) 1 3.4 (0.47–24)
Splice Site (IVS)
IVS2-1GA 1 1 DCMVT/VF F not proven 1 1 1 (100%) 1 (100%) 1 120 (17.07–860) 1 120 (17.07–860)
IVS51GT 5 1 DCMAVB F proven 1 2 2 (100%) 2 (100%) 2 16.5 (4.1–66.2) 2 16.5 (4.1–66.2)
IVS61G>A 6 1 DCMVT/VF F proven 1 11 8 (73%) 7 (63%) 6 12.3 (5.5–27.4) 5 10.3 (4.3–24.7)
Totals, n
27 94 60 35/94 (37%) 43 27
Novel mutations are in bold
AVB  atrioventricular block; CI  confidence interval; DCM  dilated cardiomyopathy; EDMD2  Emery-Dreifuss muscular dystrophy type 2; F  familial; ICD  implantable cardioverter-defibrillator; LMNA  lamin A/C; NLS  nuclear localization signal; NLS class 1 
class 1 before NLS; NLS class 2  class 2 after NLS; SCD  sudden cardiac death; VT/VF  ventricular tachycardia/fibrillation.
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Event Predictors in Dilated Cardiolaminopathies October 7, 2008:1250–60ad conduction disturbances, supraventricular arrhyth-
ias, or slightly increased LV diameter with normal LV
jection fraction but did not fulfill the diagnostic criteria
or DCM; the remaining 29 were healthy. None had
DMD2. Table 2 summarizes the baseline characteris-
ics of the entire study population. Among the 60
utated affected patients, 12 had a pacemaker implanted
efore coming to our attention.
enetic findings. Fifty-nine mutations (63%) were mis-
ense, 14 (15%) were splice site, and 21 (22%) were
ns-del/stop mutations. The 21 group of ins-del/stop mu-
ations comprised 5 stop mutations (predicting a premature
top codon), 11 frameshift mutations, and 5 in-frame
eletions predicting the loss of 2 residues. The grouping of
n-frame deletions with out-of-frame and stop mutations
Baseline Characteristics of the 94 Subjects WitLMNA Mutations According to Their Cardiologic
Table 2 Baseline Characteristics of the 94LMNA Mutations According to Thei
Characteristics
Women
Age (yrs), mean  SD (range)
Age 40 yrs*
Cardiac phenotypes at first diagnosis
In probands (n  27)
DCMAVB
DCMAVBEDMD2
DCMVT/VF
In relatives (n  67)
DCMAVB
DCMVT/VF
DCMAVBEDMD2
AVBEDMD2
Other
New York Heart Association functional class
I
II
III
IV
LVEF 35% (n  90)
LVEDV 180 ml (n  89)
sCPK 180 U/l (n  91)
Atrial fibrillation (n  91)
Atrioventricular block
Competitive sport for 10 yrs†
Soccer (low static, high dynamic)
Running (low static, high dynamic)
Basketball (moderate static, high dynamic)
Swimming (moderate static, high dynamic)
Orienteering (low static, high dynamic)
Nordic skiing (low static, high dynamic)
Tennis (low static, high dynamic)
Triathlon (high static, high dynamic)
Mutations other than missense‡
*Fisher exact test p  0.001. †Fisher exact text p  0.001 (5 affecte
not included among the competitive performers). ‡Fisher exact test p
AVNRT  atrioventricular nodal re-entry tachycardia; LVEDD  lef
volume; LVEF  left ventricular ejection fraction; sCPK  serum c
abbreviations as in Table 1.as based on numerical reasons rather than on predicted molecular effects. Concerning position, 73 mutations (78%)
ere upstream of the nuclear localization signal and 21
22%) were downstream (Table 1, Fig. 1). Estimated
enetrance of the disease is summarized in Figure 2. Thirty
utated healthy subjects (88%) were under 40 years of
ge, as compared with 33 (55%) of the affected subjects
Fisher exact test p  0.001). The overall distribution of
issense, splicing, and ins-del/stop mutations did not
iffer significantly between nonaffected and affected per-
ons (Fisher exact test p  0.16), although mutations
ther than missense tended to be more frequent in
ffected than in nonaffected persons (44% vs. 23%, p 
.073).
utcome and prognostic stratification. The 94 mutated
ubjects were observed for a median follow-up time of 57
us
cts With
diologic Status
ed (n  60) Healthy (n  34)
23 (38%) 16 (47%)
10 (19–67) 23 14 (3–59)
33 (55%) 29 (88%)
—
27 (78%)
27 (15%)
27 (7%)
 33 n  34
18 (55%) —
11 (33%)
2 (6%) —
2 (6%) —
— (LVEDD, n  2; AVNRT, n  1)
16 (27%) 34 (100%)
29 (48%) 0
11 (18%) 0
4 (7%) 0
21 (35%) 0
23 (38%) 0
15 (25%) 0
15 (25%) 0
51 (85%) 2 (1st-degree)
32 (53%) 6 (18%)
16 4
2 2
2 0
6 0
1 0
2 0
2 0
1 0
27 (45%) 8 (23%)
n, 4 practicing aerobic dance and 1 practicing classical dance, were
3.
icular end-diastolic diameter; LVEDV  left ventricular end-diastolic
phosphokinase; VT/VF  ventricular tachycardia/fibrillation; otherhStat
Subje
r Car
Affect
40
21/
4/
2/
n
d wome
 0.07
t ventronths (interquartile range 36 to 107 months). During
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October 7, 2008:1250–60 Event Predictors in Dilated Cardiolaminopathiesollow-up, 20 patients received a pacemaker and 16 received
n ICD implantation.
ll events. A total of 49 events occurred in 43 of the 60
ffected patients (mean age at the event 42 11 years; range
9 to 68 years), whereas no event was observed among the
4 mutated healthy subjects. Six nontransplanted patients
ad a later further event (heart transplantation, n 3; death
rom congestive HF, n  3) and were excluded from the
tatistical analysis. The mean follow-up was significantly
horter for younger healthy persons than for older mutated
ersons (32 20 [range 1 to 84] months vs. 65 78 [range
to 384] months, p 0.017). The linearized event rate was
.7 per 100 person-years (95% CI: 7.2 to 13.2). Cumulative
vent-free survival was 82% (95% CI: 71% to 88%) at 2
ears and 60% (95% CI: 47% to 70%) at 5 years. The
ajority of the events were SCD/ventricular arrhythmias
27 of 43, 63%), comprising 15 SCD and 12 appropriate
CD interventions detected by the device (8 ventricular
brillation and 4 sustained ventricular tachycardia). The
emaining events were all related to end-stage HF: heart
ransplantation (n  15) and death from congestive HF (n 
). The highest percentages of total events and SCD-related
vents, including appropriate ICD interventions, were ob-
erved among subjects with intervening sequence mutations
64% and 57%), followed by ins/del-stop mutations (52%
nd 38%) and by the missense mutations (38% and 19%).
he corresponding follow-up was 55  98 (median 19)
onths, 52  68 (median 33) months, and 49  55
median 36) months (p  NS).
At univariable analysis (Table 3), New York Heart
ssociation (NYHA) functional class III to IV, any disease
henotype, atrioventricular conduction disturbances, LV
jection fraction 35%, LV end-diastolic volume 180 ml,
nd history of competitive sport were all associated with
vent occurrence.
In a multivariable Cox proportional hazards model,
YHA functional class III to IV and competitive physical
Figure 2 Age-Related Penetrance of Phenotypes
in Patients With LMNA Gene Mutations
The age-related penetrance of the phenotypes in patients with lamin A/C
(LMNA) gene mutations is shown (test for trend p  0.001). CI  confidence
interval.ctivity both turned out to be strong independent predictors if events (about a 3- to 4-fold excess risk), whereas the type
f mutation did not reach statistical significance (Table 4).
o attempt prognostic stratification, we constructed a score
ased on the presence of these 2 risk factors. The cumulative
vent-free survival is illustrated in Figure 3. The hazard
atio for an event to occur was 5.20 (95% CI: 2.15 to 12.58,
 0.001) when comparing patients with 1 versus 0 risk
actors; 5.06 (95% CI: 2.45 to 10.43, p 0.001) for 2 versus
risk factor; and 26.3 (95% CI: 8.32 to 83.11, p  0.001)
or 2 versus 0 risk factors.
CD events. The SCD/ventricular arrhythmia event rate
mong the affected patients was 6.27 per 100 person-years
95% CI: 4.29 to 9.14). On phenotypic grounds, 16 of the
7 patients who experienced SCD/ventricular arrhythmia
ad DCM plus AVB; 4 had DCM plus AVB plus
DMD2; 7 had DCM plus ventricular tachycardia/
brillation. These 3 phenotypic groupings showed different
CD event rates (per 100 person-years): DCM plus AVB, 7.2
95% CI: 4.4 to 11.8); DCM plus AVB plus EDMD2, 10.1
95% CI: 3.8 to 26.9); and DCM plus ventricular tachycardia/
brillation, 13.1 (95% CI: 6.2 to 27.4; p  0.008). At
nivariable analysis (Table 5), DCM phenotypes, compet-
tive sport, and mutation type were associated with SCD
nd appropriate ICD interventions. At Cox bivariable
nalysis, splice site mutations and competitive sport were
redictors of SCD, 2.05 (95% CI: 1.01 to 4.17) and 3.8
95% CI: 1.78 to 8.08), respectively (p  0.001). For
rognostic stratification purposes, we constructed a score
ased on these 2 risk factors. The cumulative event-free
CD survival is illustrated in Figure 4. The hazard ratio for
n event to occur was 3.67 (95% CI: 1.53 to 8.77, p 
.003) for 1 versus 0 risk factors; 2.09 (95% CI: 0.98 to 4.47,
 0.056) for 2 versus 1 risk factor; and 7.68 (95% CI: 3.32
o 17.73, p  0.001) for 2 versus 0 risk factors.
iscussion
his large single-center cohort study reinforces the concept
hat DCM associated with LMNA mutations constitutes a
ighly penetrant, age-dependent, malignant disease charac-
erized by high rates of major cardiac events. Survival
nalysis suggests the possibility of prognostic stratification
ased on phenotypic and genotypic characteristics.
rom clinical suspicion to molecular diagnosis. To our
nowledge, this is the largest reported cardiologic follow-up
tudy of persons with LMNA gene mutations. Identification
f the cohort (probands and family members) was facilitated
y institutional protocols, which incorporated evolving con-
epts regarding serial family screening and peculiarities (“red
ags”) that should arouse diagnostic suspicion of LMNA
utations. In line with current knowledge (1–6,10–13,15–
7), identification of the probands was most often based on
he combination of DCM and AVB in the context of
on–X-linked and nonmatrilinear myopathy. Co-existent
yopathy (EDMD2 or variable myopathy) (8-11) andncreased serum creatine phosphokinase levels alone were
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Table 3 Data at Time of First Diagnosis: Prognostic Factors for Events in 94 Patients With LMNA Mutations at Univariable Analysis
Patient Characteristic n  94
Events
(% of Mutated)
Rate (95% CI)
(Events/100 Person-Years)
p Value
(Log-Rank Test)
Gender 0.171
Male 55 30 (54%) 11.4 (8–16.5)
Female 39 13 (33%) 7.3 (4.3–12.6)
Age, yrs 0.137
0–19 15 1 (7%) 2.3 (0.3–16.3)
20–39 47 20 (42%) 8.9 (5.7–13.8)
40–59 29 20 (69%) 12.2 (7.8–19.1)
60 3 2 (67%) 29.8 (7.4–100)
Age, yrs 0.121
20 15 1 (7%) 2.3 (0.3–16.3)
20 79 42 (53%) 10.6 (7.8–14.4)
Age, yrs 0.101
40 62 21 (34%) 7.8 (5.1–12.0)
40 32 22 (69%) 12.9 (8.4–19.8)
Competitive sport (n  89) 0.001
No 51 14 (27%) 4.7 (2.7–8.0)
Yes (traditional sport listed) 38 25 (66%) 18.3 (12.4–27.1)
NYHA functional class 0.001
I–II (including 33 healthy carriers) 79 28 (35%) 7.3 (5–10.5)
III–IV 15 15 (100%) 30.8 (18.3–52.1)
sCPK (n  91), mU/ml 0.250
180 76 31 (41%) 8.5 (5.8–12)
180 15 9 (60%) 12.7 (6.6–24.4)
Phenotype 0.001
Healthy mutated patients 29 0 (0%) 0
DCMAVB 40 29 (72%) 12.6 (8.7–18.3)
AVBEDMD2 (including 6 with DCM) 8 4 (50%) 10.1 (3.8–26.9)
DCMVT/VF 12 10 (83%) 18.7 (10.0–34.7)
Early pre-clinical signs 5 0 (0%) 0
AF (n  91) 0.448
No 76 30 (39%) 8.6 (5.9–12.3)
Yes 15 10 (67%) 11.0 (5.9–20.5)
Pacemaker 1st diagnosis (n  90) 0.167
No 78 28 (36%) 8 (5.5–11.6)
Yes 12 11 (92%) 13.9 (7.7–25.2)
AVB at the time of the first diagnosis 0.010
No 43 8 (17%) 4.9 (2.4–9.8)
Yes (including 1 AF with EPS demonstration of AVB) 51 35 (68%) 12.7 (9.1–17.8)
Type of mutation 0.235
Missense 59 23 (39%) 8.4 (5.6–12.8)
Splicing 14 9 (64%) 14.6 (7.6–28.1)
Ins-del/stop 21 11 (52%) 10.1 (5.6–18.2)
Type of mutation 0.248
Missense 59 23 (39%) 8.4 (5.6–12.8)
Non-missense 35 20 (57%) 11.7 (7.6–18.2)
No splicing versus splicing 0.100
No splicing 80 34 (42%) 8.9 (6.4–12.6)
Splicing 14 9 (64%) 14.6 (7.6–28.1)
Hierarchical cluster NLS mutations 0.225
Class 1 73 34 (46%) 10.7 (7.6–15.0)
Class 2 21 9 (43%) 7.4 (5.8–14.2)
LVEF (n  90), % 0.001
35 21 19 (90%) 23.2 (14.6–36.8)
35 69 20 (29%) 5.7 (3.7–8.9)Continued on next page
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October 7, 2008:1250–60 Event Predictors in Dilated Cardiolaminopathieslso considered, after excluding an X-linked or matrilineal
nheritance, especially in the presence of AVB, an unusual
eature in X-linked DCM (25). In our cohort, most pro-
ands had familial disease, with only 1 case proven to be de
ovo. It should be noted that, due to selection bias consid-
rations, including the characteristics of the institutional
etting and the family screening protocol, the present study
ould not provide information regarding the prevalence of
MNA gene defects among patients with DCM.
henotype considerations. Within our families, the over-
ll penetrance was high and progressively increased with
ge: by 60 years, the penetrance was complete, and all
utated persons showed the phenotype, irrespective of
utation type. Among LMNA mutated subjects, DCM is
dentification of Prognostic Factors of Events in 94atients With LMNA Mutations: Multivariableox Model*
Table 4
Identification of Prognostic Factors of Events in 94
Patients With LMNA Mutations: Multivariable
Cox Model*
Patient Characteristics HR (95% CI)
p Value
(Multivariable
Cox Model)
Competitive physical activity 0.003
No 1
Yes 3.38 (1.50–7.61)
NYHA functional class 0.001
I–II 1
III–IV 4.28 (1.78–10.20)
AVB 0.252
No 1
Yes 2.72 (0.49–15.04)
Type of mutation† 0.069
Missense 1
Splice site 2.31 (1.13–4.74) 0.022
Ins-del/stop 1.14 (0.32–4.09) 0.839
LVEF, % 0.448
35 1
35 0.99 (0.96–1.02)
Gender 0.595
Male 1
Female 0.83 (0.42–0.64)
After backward stepwise regression
(p-to-remove  0.2)‡
NYHA functional class III–IV 5.29 (2.62–10.66) 0.001§
Competitive physical activity 4.94 (2.17–11.25) 0.001§
Model chi-square (7 df)  41.93, p  0.001; model discrimination: Harrell’s C  0.79; model
alibration: shrinkage coefficient  0.83. †The first p value (bold) refers to the type of mutation,
verall; the other p values refer to the comparison with the reference category. ‡After backward
tepwise regression with p-to-remove of 0.2, competitive physical activity, NYHA functional class,
acemaker implantation, and type of mutation were retained in the model. §Cox model with
ontinued
Table 3 Continued
Patient Characteristic n  94
LVEDV (n  89), ml
180 66
180 23
F  atrial fibrillation; CI  confidence interval; EPS  electrophysiological study; Ins-Del/Stop
ssociation; other abbreviations as in Tables 1 and 2.tepwise selection.
HR  hazard ratio; other abbreviations as in Tables 1 to 3.are under the age of 20 years. This observation is in line
ith the finding reported by Benedetti et al. (26) that onset
f the cardiomyopathy phenotype tends to occur at a later
ge (adulthood) in comparison to the EDMD2 phenotype
early childhood). Of note, the distribution of nonmissense
utations in our cohort (44% in affected patients vs. 23% in
naffected subjects) is also broadly in line with the obser-
ation by Benedetti et al. (26) of a high prevalence in the
ardiomyopathy phenotype of nonmissense mutations. The
bservation that the majority (78%) of our DCM-affected
robands had mutations upstream of the nuclear localiza-
ion signal spanning residues 416 to 423 is also in line with
he study conducted by Hegele (24 using hierarchical cluster
nalysis, where these upstream mutations were strongly
ssociated with class 1 (cardiac/myopathy phenotypes) with
espect to class 2 laminopathies (partial lipodystrophy,
rogeria syndromes, and mandibuloacral dysplasia).
Our study is not informative regarding the reasons for the
ommonly observed phenomenon, described elsewhere
2,4,5,17), of early onset of AVB before DCM. We ob-
erved patients who first presented with AVB and later had
CM as well as patients who showed both DCM and AVB
t the time of their first diagnosis (5). Prospective long-term
ollow-up of healthy mutated subjects should help elucidate
he timing of expression of the phenotypic traits.
Figure 3 Kaplan-Meier Event-Free Survival
Kaplan-Meier event-free survival stratified by 2 independent risk factors
(RF): New York Heart Association functional class III to IV and competitive sports.
Events
of Mutated)
Rate (95%CI)
(Events/100 Person-Years)
p Value
(Log-Rank Test)
0.001
0 (30%) 6.3 (4.0–9.7)
8 (78%) 16.4 (10.3–26.1)
rtion/deletion and stop mutations; NLS  nuclear localization signal; NYHA  New York Heart(%
2
1
D*
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Table 5 Data at Time of First Diagnosis: Prognostic Factors of SCD in 94 Mutated Patients at Univariable Analysis*
Variable n  94
SCD and ICD Intervention
(% of Mutated)
Rate (95% CI)
(Events/100 Person-Years)
p Value
(Log-Rank Test)
Gender 0.214
Male 55 19 (34%) 7.5 (4.78–11.76)
Female 39 8 (20%) 4.51 (2.25–9.02)
Age, yrs 0.249
20 15 1 (7%) 2.29 (0.32–16.32)
20 79 26 (33%) 6.71 (4.57–9.86)
Age, yrs 0.058
40 62 13 (21%) 4.85 (2.81–8.35)
40 32 14 (44%) 8.61 (5.10–14.54)
NYHA functional class 0.082
I 50 6 (12%) 3.16 (1.42–7.05)
II 29 16 (55%) 8.16 (5.00–13.33)
III 11 5 (45%) 13.03 (5.42–31.31)
IV 4 0 (0%) 0
NYHA functional class III–IV 0.281
No (I–II) 79 22 (28%) 5.71 (3.76–8.67)
Yes (III–IV) 15 5 (33%) 11.01 (4.58–26.46)
sCPK (n  91), mU/ml 0.366
180 76 18 (24%) 5.01 (3.16–7.96)
180 15 6 (40%) 8.46 (3.80–18.84)
Phenotypes 0.00001
Healthy mutated 29 0 (0%) 0
DCMAVB 40 16 (40%) 7.22 (4.4–11.8)
DCMAVBEDMD2 6 4 (67%) 10.1 (3.8–26.9)
AVBEDMD2 2 0 (0%) 0
DCMVT/VF 12 7 (58%) 13.1 (6.2–27.4)
Pre-clinical signs 5 0 (0%) 0
EDMD2 0.160
No 86 22 (25%) 4.92 (3.13–7.71)
Yes 8 5 (62%) 11.54 (4.80–27.73)
Atrial fibrillation (n  91) 0.373
No 76 17 (22%) 5.01 (3.11–8.06)
Yes 15 7 (47%) 7.73 (3.68–16.22)
Pacemaker at first diagnosis (n  90) 0.851
No 78 19 (24%) 5.42 (3.45–8.49)
Yes 12 5 (42%) 6.33 (2.63–15.22)
AVB 0.051
No 43 6 (14%) 3.66 (1.64–8.14)
Yes 51 21 (41%) 7.87 (5.13–12.07)
Competitive sport (n  89) 0.0005
No 51 8 (16%) 2.86 (1.43–5.73)
Yes 38 19 (50%) 12.54 (8.00–19.66)
Type of mutation 0.027
Missense 59 11 (19%) 4.22 (2.34–7.63)
Splicing 14 8 (57%) 13.00 (6.50–26.00)
Ins-del/stop 21 8 (38%) 7.34 (3.67–14.68)
LVEF (n  90), % 0.137
35 21 7 (33%) 4.58 (2.80–7.48)
35 69 16 (23%) 9.01 (4.29–18.91)
LVEDV (n  89), ml 0.445
180 66 16 (24%) 6.38 (3.04–13.39)
180 23 7 (30%) 5.02 (3.08–8.20)Rate of events per 100 person-years: 6.27 (interquartile range 4.29 to 9.14).
Abbreviations as in Tables 1 to 3.
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October 7, 2008:1250–60 Event Predictors in Dilated Cardiolaminopathiesutcome and prognostic stratification. Patients with
MNA gene mutations have high rates of major cardiac
vents (17). The major events recorded in our cohort were
elated to life-threatening arrhythmias or end-stage HF and
lways occurred in the context of DCM. The SCD-related
vents, including appropriate ICD interventions for life-
hreatening arrhythmias, were more frequent. The high
ates of SCD and other SCD-related events are in line with
he meta-analysis by van Berlo et al. (17), although we
bserved no major cardiac event before onset of DCM.
owever, the spectrum of our cardiac phenotypes reflects
he DCM study setting, which does not include families in
hich myopathy was the isolated or major phenotype and
hich only partially overlaps with the setting of permanent
ardiac pacing in patients without DCM. In a recent study
27) including 19 patients who underwent permanent pac-
ng and ICD implantation solely on the basis of LMNA
ene mutations associated with cardiac conduction defects
nd normal ventricular function, 8 of 19 (42%) received an
ppropriate ICD intervention, suggesting high risk of SCD
efore onset of HF. In our cohort, only 2 unrelated healthy
oung mutated subjects, both sons of patients with DCM
lus AVB, had first-degree AVB with normal ventricular
ize and function. An important difference between our
oung healthy mutated subjects and the patients described
y Meune et al. (27) is that our 2 young mutated persons
ith AVB did not yet require permanent pacing, and
herefore, the indication for pacemaker and ICD implanta-
ion did not seem appropriate. Regarding myopathy traits,
e observed overlapping phenotypes characterized by DCM
lus AVB and EDMD2 in 4 of our families; however, the
yopathy was mild, and the most relevant clinical problems
ere the DCM and arrhythmias. It is possible that, in the
yology setting, patients with less cardiac remodeling are
Figure 4 Kaplan-Meier SCD Event-Free Survival
Kaplan-Meier sudden cardiac death (SCD) event-free survival stratified
by 2 independent risk factors (RF): splicing mutations and competitive sports.ore common or that less attention is dedicated to early fardiac dysfunction, with SCD occurring in patients with
pparently normal hearts.
At univariable analysis, several factors were associated with
he risk of events both related to heart failure and to life-
hreatening ventricular arrhythmias. Surprisingly, however, at
ultivariable analysis, neither AVB nor pacemaker implanta-
ion turned out to be predictors of events, supporting the
oncept that AVB is a clinical marker of cardiolaminopathies,
ather than an event predictor. In keeping with the results of
he meta-analysis by van Berlo et al. (17), the pacemaker did
ot appear to protect from SCD. Of note, none of our patients
ith ICD died suddenly, but ICD allowed us to bridge 3
atients to heart transplantation.
Only 2 factors remained significant predictors at multi-
ariable analysis: NYHA functional class III to IV (the
trongest predictor of overall events) and a history of high
ynamic competitive sports of at least 10 years. This interval
s somehow arbitrary, as we did not have models or prior
eference data for inherited DCMs. Obviously, the age
nfluences the lower prevalence of athletes in the group of
he younger healthy mutated persons, thus helping to
xplain the high association with the risk of events in the
ultivariable analysis. However, the perception of the
egative effect of competitive sport on the disease evolution
as a daily experience when screening and regularly moni-
oring families of our series. We are aware of the beneficial
ffects of sport on heart performance; however, the myocyte
olecular and structural derangement associated with the
MNA gene defects could interfere with the potential
enefit of physical training.
NYHA functional class III to IV was the strongest
redictor of total events but not of SCD, which seemed to
e more influenced by competitive sport and type of
utation. Competitive sport and presence of splicing mu-
ations appeared to help the risk stratification of SCD at
ox bivariable analysis. The possible prognostic relevance of
plicing mutations is an attractive hypothesis, and nonmis-
ense mutations were associated with the highest rate of
vents. However, given the particular characteristics of the
etting of this single study, caution is required before the
resence of a splicing mutation is used for risk stratification
n clinical practice. It is noteworthy that we were unable to
etect any association between the mutation regions classi-
ed by Hegele (24) and outcome. It is likely that this
lassification is useful for predicting phenotypes, rather than
heir severity or related events.
linical implications. Once DCM develops in persons
ith LMNA gene mutations, arrhythmogenic risk seems to
ncrease, and ICD implantation should probably be per-
ormed earlier than suggested by current guidelines (28).
e think that cardiolaminopathies with DCM phenotype
eserve tailored clinical monitoring, including early indica-
ions for ICD implantation so as to prevent SCD and
rovide a possible bridge to heart transplantation in end
tage HF. This concept fits well with proposals to bring
orward ICD implantation in patients who are candidates
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Event Predictors in Dilated Cardiolaminopathies October 7, 2008:1250–60or pacemaker implantation due to AVB (17,26,27). Given
he increased risk of all major events and SCD in LMNA-
ositive subjects with clinically overt disease, highly com-
etitive sports should be discouraged after detection of any
henotype. For mutated healthy persons, only further
ollow-up will give an answer on the suitability for agonistic
ctivity. While awaiting these data, we suggest maintaining
he sport activity at a nonagonistic level.
onclusions
ong-term follow-up of a cohort of families with dilated
ardiolaminopathies identified at a single center confirms
heir high risk of major events, particularly of SCD and
entricular arrhythmias. The emerging consensus in high-
ighting the risk of life-threatening arrhythmic events for
ersons with LMNA gene mutations is a warning that
hould lead to considering special indications for ICD
mplantation in this group of patients. We think that young
ealthy mutated patients should probably be advised to
njoy noncompetitive physical leisure activities or low dy-
amic, noncompetitive sport activities.
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